Lutropin alfa

Generic Name: Lutropin alfa

Brand Names: Luveris, Pergoveris

Drug Type: Biotech

CAS Number: 152923-57-4

Unique Ingredient Identifier: 3JGY52XJNA

Background: Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein made up of monomeric units. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum. In males, LH stimulates Leydig cell to produce testosterone.

Indication: For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)

Clinical Trials

FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients

Phase 3

Not yet recruiting

Conditions: Fertility Preservation

Interventions: Drug: Luveris

First Posted Date: 2024-01-29

Last Posted Date: 2024-01-29

Lead Sponsor: Ellen Greenblatt

Target Recruit Count: 140

Registration Number: NCT06227949

Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders

Phase 4

Withdrawn

Conditions: Poor Response to Ovulation Induction

Interventions: Drug: Lutropin alfa
Drug: Follitropin alfa
Diagnostic Test: Endometrial biopsy

First Posted Date: 2022-06-06

Last Posted Date: 2024-02-28

Lead Sponsor: CRG UZ Brussel

Registration Number: NCT05405686

Pergoveris FD and Liquid China BE Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pergoveris FD
Drug: Pergoveris Liquid
Drug: Gonal-f
Drug: Luveris

First Posted Date: 2021-05-24

Last Posted Date: 2022-06-15

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 72

Registration Number: NCT04899193

Locations: 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, China

Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men

Phase 2

Recruiting

Conditions: Acquired Hypogonadotropic Hypogonadism

Interventions: Drug: Lutropin alfa
Drug: Human chorionic gonadotropin

First Posted Date: 2019-12-06

Last Posted Date: 2023-07-20

Lead Sponsor: Azienda Ospedaliero-Universitaria di Modena

Target Recruit Count: 32

Registration Number: NCT04189133

Locations: 🇮🇹
Fondazione IRCCS Ca ' Grande Ospedale Maggiore Policlinico, Milan, Italy
🇮🇹
Unit of Endocrinology of Modena, Modena, Italy
🇮🇹
Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università degli Studi di Napoli "Federico II", Naples, Italy

and more 2 locations